Analysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Target Price at $11.60

C4 Therapeutics, Inc. (NASDAQ:CCCC) has earned an average rating of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $11.60.

Several equities research analysts have weighed in on the stock. Stephens assumed coverage on shares of C4 Therapeutics in a research report on Monday, November 18th. They set an “equal weight” rating and a $4.00 price target for the company. Wells Fargo & Company raised shares of C4 Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $8.00 to $12.00 in a research report on Thursday, December 19th. Finally, UBS Group raised shares of C4 Therapeutics to a “hold” rating in a research report on Friday, February 14th.

C4 Therapeutics Stock Performance

Shares of C4 Therapeutics stock opened at $3.01 on Wednesday. C4 Therapeutics has a 52-week low of $2.79 and a 52-week high of $11.88. The stock has a market capitalization of $212.47 million, a price-to-earnings ratio of -1.77 and a beta of 2.95. The company has a fifty day moving average of $3.64 and a 200-day moving average of $4.91.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CCCC. Sei Investments Co. bought a new position in shares of C4 Therapeutics in the 4th quarter worth about $45,000. Point72 DIFC Ltd bought a new position in shares of C4 Therapeutics in the 3rd quarter worth about $51,000. Kazazian Asset Management LLC bought a new position in shares of C4 Therapeutics in the 4th quarter worth about $51,000. China Universal Asset Management Co. Ltd. bought a new position in shares of C4 Therapeutics in the 4th quarter worth about $54,000. Finally, Cynosure Group LLC bought a new position in shares of C4 Therapeutics in the 3rd quarter worth about $57,000. 78.81% of the stock is currently owned by institutional investors.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.